This anti-BCMA antibody is a purified, recombinant human monoclonal antibody which recognizes the human BCMA protein. BCMA is also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17) and is expressed on the surface of plasma cells. BCMA is important for plasma cell differentiation and B cell proliferation. BCMA is a validated therapeutic target in multiple myeloma. The first anti-BCMA CAR-T cell therapy (idecabt agene vicleucel) was approved by the FDA in 2021.